Objective: The purpose of this study was to determine the efficacy of concurrent chemoradiotherapy using conventional radiotherapy combined with low-dose daily 5-fluorouracil (5FU) and cisplatin (CDDP) for the locally unresectable head and neck cancer patients. Patients and Methods: From September 1996 through December 2000, we carried out a phase II study of concurrent chemoradiotherapy with low-dose CDDP plus 5FU for the treatment of patients with unresectable squamous cell carcinoma of the head and neck. Chemoradiotherapy consisted of irradiation with 1.6–2.0 Gy/day for 5 days per week up to a total dose 68 Gy and CDDP 3 mg/m2 by intravenous infusion over 1 h plus 5FU 150 mg/m2 by intravenous infusion over 24 h per day for 5 days per week. Results: Ninety percent of the patients had stage IV disease, including 65% of patients with T4 disease. Thirty-three patients (83%) received the full treatment as planned; 39 (98%) received full-dose radiotherapy and 33 (83%) full-dose chemotherapy. Of the 40 patients evaluable for response, 20 (50%) achieved complete response (CR) and 12 (30%) partial response with an overall response rate of 80%. Among the 20 CR patients, 15 underwent endoscopic blind biopsies and 4 had positive lesions. The most frequently observed toxicity was mucositis. Ten patients developed grade III mucositis, and 3 patients required enteral nutritional support through a feeding tube. Grade III leukopenia, anemia and thrombocytopenia were observed in 28, 25 and 20% of the patients, respectively. The median duration of follow-up at the time of analysis was 18 months. The median survival time was 23 months. The responders survived longer (34 months) than the nonresponders (4 months; p < 0.05). Conclusion: This regimen is safe and efficacious in the treatment of patients with advanced unresectable head and neck cancer.

Keywords:
Head and neck cancer, Chemoradiotherapy, Cisplatin, low dose, 5-Fluorouracil
1.
Aisner J, Jacobs M, Sinabaldi V, Gray W, Eisenberger M: Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin Oncol 1994;21:35–44.
2.
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685–1690.
3.
Lefebvre J-L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization of Research and Treatment of Cancer Phase III trial. J Nat Cancer Inst 1996;88:890–899.
4.
Munro AJ: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83–91.
5.
El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838–847.
6.
Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analysis of updated individual data. Lancet 2000;355:949–955.
7.
Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819–1824.
8.
Kohno N, Kitahara S, Kawaida M, Ichikawa G, Shirasaka T: Outpatient setting chemotherapy for recurrent and/or advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 1999;4:285–288.
9.
Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer. Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088–1095.
10.
Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18:1458–1464.
11.
Wibault P, Bensmaine MA, de Forni M, Armand JP, Tellez Bernal E, Guillot T, Recondo G, Domenge C, Janot F, Borel C, Luboinski B, Eschwege F, Cvitkovic E: Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: A phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J Clin Oncol 1996;14:1192–1200.
12.
Taylor SG, Murthy AK, Caldarelli DD, Showel JL, Kiel K, Griem KL, Mittal BB, Kies M, Hutchinson JC Jr, Holinger LD: Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J Clin Oncol 1989;7:846–856.
13.
Johnson C, Silverman L, Clay L, Schmidt-Ullrich R: Radiotherapeutic management of bulky cervical lymphadenopathy in squamous cell carcinoma of the head and neck: Is post-radiotherapy neck dissection necessary? Radiat Oncol Investig 1998;6:52–57.
14.
Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, Geara F, Clayman GL, Shin DM, Callender DL, Khuri FR, Goepfert H, Hong WK, Peters LJ: Phase I/II trial of radiation with chemotherapy ‘boost’ for advanced squamous cell carcinomas of the head and neck: Toxicities and responses. J Clin Oncol 1999;17:2390–2395.
15.
Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998;16:1318–1324.
16.
Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Pronsnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798–1804.
17.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–2086.
18.
Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, Friedman MA, Kohler M, McWhirter K, Carter SK: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410–1418.
19.
Adelstein DJ, Kalish LA, Adams GL, Wanger H, Oken MM, Remick SC, Mansour EG, Haselow RE: Concurrent radiation and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136–2142.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.